Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention

被引:83
|
作者
Vaidya, Kaivan [1 ]
Tucker, Bradley [2 ,3 ]
Kurup, Rahul [1 ,2 ]
Khandkar, Chinmay [1 ]
Pandzic, Elvis [4 ]
Barraclough, Jennifer [1 ,2 ]
Machet, Joshua [3 ]
Misra, Ashish [2 ]
Kavurma, Mary [2 ]
Martinez, Gonzalo [5 ]
Rye, Kerry-Anne [3 ]
Cochran, Blake J. [3 ]
Patel, Sanjay [1 ,2 ,6 ]
机构
[1] Royal Prince Alfred Hosp, Sydney, NSW, Australia
[2] Heart Res Inst, Sydney, NSW, Australia
[3] UNSW Sydney, Sch Med Sci, Sydney, NSW, Australia
[4] UNSW Sydney, Mark Wainwright Analyt Ctr, Biomed Imaging Facil, Sydney, NSW, Australia
[5] Pontificia Univ Catolica Chile, Div Cardiovasc Dis, Santiago, Chile
[6] Univ Sydney, Sydney Med Sch, Sydney, NSW, Australia
来源
JOURNAL OF THE AMERICAN HEART ASSOCIATION | 2021年 / 10卷 / 01期
关键词
acute coronary syndrome; inflammation; percutaneous coronary intervention; pharmacology; MYOCARDIAL-INFARCTION; PATHOPHYSIOLOGY; PREVENTION; THERAPY; UPDATE; SINUS;
D O I
10.1161/JAHA.120.018993
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Release of neutrophil extracellular traps (NETs) after percutaneous coronary intervention (PCI) in acute coronary syndrome (ACS) is associated with periprocedural myocardial infarction, as a result of microvascular obstruction via pro-inflammatory and prothrombotic pathways. Colchicine is a well-established anti-inflammatory agent with growing evidence to support use in patients with coronary disease. However, its effects on post-PCI NET formation in ACS have not been explored. METHODS AND RESULTS: Sixty patients (40 ACS; 20 stable angina pectoris) were prospectively recruited and allocated to colchicine or no treatment. Within 24 hours of treatment, serial coronary sinus blood samples were collected during PCI. Isolated neutrophils from 10 patients with ACS post-PCI and 4 healthy controls were treated in vitro with colchicine (25 nmol/L) and stimulated with either ionomycin (5 mu mol/L) or phorbol 12-myristate 13-acetate (50 nmol/L). Extracellular DNA was quantified using Sytox Green and fixed cells were stained with Hoechst 3342 and anti-alpha tubulin. Baseline characteristics were similar across both treatment and control arms. Patients with ACS had higher NET release versus patients with stable angina pectoris (P<0.001), which was reduced with colchicine treatment (area under the curve: 0.58 versus 4.29; P<0.001). In vitro, colchicine suppressed unstimulated (P<0.001), phorbol 12-myristate 13-acetate-induced (P=0.009) and ionomycin-induced (P=0.002) NET formation in neutrophils isolated from patients with ACS post-PCI, but not healthy controls. Tubulin organization was impaired in neutrophils from patients with ACS but was restored by colchicine treatment. CONCLUSIONS: Colchicine suppresses NET formation in patients with ACS post-PCI by restoring cytoskeletal dynamics. These findings warrant further investigation in randomized trials powered for clinical end points.
引用
收藏
页码:1 / 13
页数:22
相关论文
共 50 条
  • [21] Adverse clinical events after percutaneous coronary intervention in very elderly patients with acute coronary syndrome
    Kawamoto, Takanori
    Otsuki, Hisao
    Arashi, Hiroyuki
    Jujo, Kentaro
    Oka, Toshiaki
    Mori, Fumiaki
    Tanaka, Hiroyuki
    Sakamoto, Tomohiro
    Ishii, Yasuhiro
    Terajima, Yutaka
    Yagi, Masahiro
    Takagi, Atsushi
    Haruta, Shoji
    Yamaguchi, Junichi
    CARDIOVASCULAR INTERVENTION AND THERAPEUTICS, 2024, 39 (04) : 438 - 447
  • [22] Clinical efficacies of percutaneous coronary intervention in patients with maintaining hemodialysis combined with acute coronary syndrome
    Wu, Hua
    Liu, Panpan
    Chen, Chen
    Gao, Bihu
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL MEDICINE, 2016, 9 (11): : 22398 - 22402
  • [23] Treatment patterns in patients with acute coronary syndrome undergoing percutaneous coronary intervention
    Ferrieres, Jean
    Bakhai, Ameet
    Iniguez, Andres
    Schmitt, Claude
    Sartral, Magali
    Belger, Mark
    Zeymer, Uwe
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (09) : 2193 - 2202
  • [24] Neutrophil-to-lymphocyte ratio and prognosis in patients undergoing percutaneous coronary intervention for acute coronary syndrome
    Ha, Edward T.
    Yee, Aaron
    Peterson, Stephen J.
    Kobayashi, Yuhei
    Sacchi, Terrence
    Parikh, Manish
    Brener, Sorin J.
    CARDIOVASCULAR REVASCULARIZATION MEDICINE, 2024, 60 : 29 - 34
  • [25] Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention
    Bavishi, Chirag
    Trivedi, Vrinda
    Singh, Mandeep
    Katz, Edward
    Messerli, Franz H.
    Bangalore, Sripal
    AMERICAN JOURNAL OF MEDICINE, 2017, 130 (11) : 1325.e1 - 1325.e12
  • [26] RISK FACTORS FOR NO-REFLOW PHENOMENON AFTER PERCUTANEOUS CORONARY INTERVENTION IN PATIENTS WITH ACUTE CORONARY SYNDROME
    Liang, Tian
    Liu, Min
    Wu, Chengyu
    Zhang, Qing
    Lu, Lei
    Wang, Zhongliang
    REVISTA DE INVESTIGACION CLINICA-CLINICAL AND TRANSLATIONAL INVESTIGATION, 2017, 69 (03): : 139 - 145
  • [27] Antithrombotic strategies in patients undergoing percutaneous coronary intervention for acute coronary syndrome
    Pham, Son V.
    Pham, Phuong-Chi T.
    Pham, Phuong-Mai T.
    Miller, Jeffrey M.
    Pham, Phuong-Thu T.
    Pham, Phuong-Anh T.
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2010, 4 : 203 - 220
  • [28] Effects of Acute Coronary Syndrome and Stable Coronary Artery Disease on Bleeding and Ischemic Risk After Percutaneous Coronary Intervention
    Natsuaki, Masahiro
    Morimoto, Takeshi
    Shiomi, Hiroki
    Kadota, Kazushige
    Tada, Tomohisa
    Takeji, Yasuaki
    Matsumura-Nakano, Yukiko
    Yoshikawa, Yusuke
    Watanabe, Hirotoshi
    Yamamoto, Ko
    Imada, Kazuaki
    Domei, Takenori
    Yamaji, Kyohei
    Kaneda, Kazuhisa
    Taniguchi, Ryoji
    Ehara, Natsuhiko
    Nawada, Ryuzo
    Toyofuku, Mamoru
    Shinoda, Eiji
    Suwa, Satoru
    Tamura, Toshihiro
    Inada, Tsukasa
    Matsuda, Mitsuo
    Aoyama, Takeshi
    Sato, Yukihito
    Furukawa, Yutaka
    Ando, Kenji
    Nakagawa, Yoshihisa
    Kimura, Takeshi
    CIRCULATION JOURNAL, 2021, 85 (11) : 1928 - +
  • [29] Routine early versus deferred provisional tirofiban treatment in patients with acute coronary syndrome undergoing percutaneous coronary intervention
    Zhang, You
    Gao, Chuanyu
    Liu, Hongzhi
    Wang, Xianpei
    Yang, Honghui
    Li, Muwei
    Wang, Xianqing
    Zhu, Zhongyu
    Hu, Dayi
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2013, 40 (04) : 289 - 294
  • [30] Acute Coronary Syndrome after Percutaneous Coronary Intervention: State of the Problem and Clinical Practice Data br
    Egorova, I. S.
    Vezikova, N. N.
    RATIONAL PHARMACOTHERAPY IN CARDIOLOGY, 2022, 18 (06) : 669 - 675